Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years

NCT02137707 is registered in ClinicalTrials.gov with McGill University as lead sponsor.

NCT NCT02137707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02137707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years
Lead sponsor
McGill University
Phase
Observational
Overall status
Completed
Start date
November 30, 2012
Completion date
October 30, 2018
Enrollment
135 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis-relapsing-remitting